Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mge.2003.333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A vision-language foundation model for precision oncology.
Nature
January 2025
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Clinical decision-making is driven by multimodal data, including clinical notes and pathological characteristics. Artificial intelligence approaches that can effectively integrate multimodal data hold significant promise in advancing clinical care. However, the scarcity of well-annotated multimodal datasets in clinical settings has hindered the development of useful models.
View Article and Find Full Text PDFImmune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers.
J Chemother
January 2025
Department of Internal Medicine, Division of Hematology & Oncology, University of Virginia Health, Charlottesville, VA, USA.
Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as immune-related adverse events (IRAEs). Several studies have shown improved treatment responses in patients with IRAEs compared to those without IRAEs in various cancer types such as melanoma and non-small cell lung cancer.
View Article and Find Full Text PDFPD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024.
Hum Vaccin Immunother
December 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients' quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors.
View Article and Find Full Text PDFZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis.
Clin Transl Med
January 2025
Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.
Backgroud: Oesophageal cancer ranks among the most prevalent malignant tumours globally, primarily consisting of oesophageal squamous cell carcinoma (ESCC). Cancer stem cells (CSCs) accelerate the progression ESCC via their strong self-renewal and tumourigenic capabilities, presenting significant clinical challenges due to increased risks of recurrence and drug resistance.
Methods: Our previous study has reported WYC-209, which is capable of inducing apoptosis of CSCs in melanoma and hepatoma, but is ineffective against ESCC.
A Rare and Rapidly Progressive Case of Primary Esophageal Malignant Melanoma in an Elderly Patient.
Cureus
November 2024
Internal Medicine, Unidade Local de Saúde do Alto Minho, Viana do Castelo, PRT.
Primary malignant melanoma of the esophagus (PMME) is a rare malignancy typically associated with poor prognosis, particularly in elderly patients. Here, we present the case of an 85-year-old female patient with a three-month history of progressive dysphagia and heartburn-related epigastric pain. Endoscopy revealed a polypoid esophageal lesion, confirmed as melanoma via biopsy with positive immunohistochemical staining for Melan-A and SOX-10.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!